Skip to main content

Table 1 Phase 3 trials of chemotherapy in previously untreated CLL patients

From: Therapeutic advancement of chronic lymphocytic leukemia

Reference (year)

Regimen

Number of patients

Median age (years)

CR,%

ORR,%

Median PFS (months)

OS

Rai, 2000 [4]

Chlorambucil

181

62

4

37

14

Median 56 m

 

Fludarabine

170

64

20

63

20

Median 66 m

Eichhorst, 2009 [5]

Chlorambucil

100

70

0

51

18

Median 64 m

 

Fludarabine

93

71

7

72

19

Median 46 m

Knauf, 2009 [7]

Chlorambucil

157

66

2

31

8.3

NR

 

Bendamustine

162

63

31

68

21.6

NR

Eichhorst, 2006 [9]

Fludarabine

164

59

7

83

20

81% at 3 y

 

FC

164

58

24

94

48

80% at 3 y

Catovsky, 2007 [10]

Fludarabine

194

64

15

80

23

52% at 5 y

 

FC

196

65

38

94

43

54% at 5 y

 

Chlorambucil

387

65

7

72

20

59% at 5 y

Flinn, 2007 [11]

Fludarabine

137

61

5

60

19

80% at 2 y

 

FC

141

61

23

74

32

79% at 2 y

Robak, 2010 [13]

CC

192

58

47

88

28

62.4% at 4 y

 

FC

203

59

46

82

27

60.6% at 4 y

Robak, 2011 [15]

Cladribine

174

61

21

78

27.2

Median 45 m

 

CC

171

62

29

83

22.4

Median 48 m

 

CMC

163

59

36

80

25.6

Median 46 m

  1. Abbreviations: CC, cladribine, cyclophosphamide; CMC, cladribine, cyclophosphamide, mitoxantrone; CR, complete response; FC, fludarabine, cyclophosphamide; NR, not researched; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.